Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Chronic Heart Failure Guidelines

05.09.2005


Chronic heart failure (CHF) is common, deadly, disabling, costly but fortunately - treatable. During the last ten to 15 years, treatment of CHF has been dramatically improved by pharmacological therapy and devices. Treatment also has become more complicated. The Guidelines are intended as a support for practising physicians and other health care professionals as most patients with CHF are treated by non-cardiologists. Heart failure clinics are common in Scandinavia with specialized nurses managing patients.



Diagnosis

Symptoms and signs are essential for the diagnosis as they alert the observer to the possibility that heart failure exists. The clinical suspicion of heart failure must be confirmed by more objective tests particularly aimed at assessing cardiac function.


Treatment

Treatment of CHF is aimed at prolonging life and reducing morbidity and symptoms. Quality of life in patients with CHF is reduced as exemplified by frequent hospitalisations when symptoms increase. Hospitalisations for heart failure are costly and reductions are important.

Therapy should include a combination of agents counteracting the adrenergic and renin-angiotensin systems. New neurohormonal antagonists, ACE-inhibitors and beta-blockers together with diuretics make the platform for therapy.

The most recent pharmacologic experience demonstrates the value of ARBs not only as an alternative to ACE-inhibitors but also in addition to these important agents both in CHF as well as in heart failure after MI. The role of aldosterone antagonists has expanded to left ventricular dysfunction after a myocardial infarction.

The role of device therapy (biventricular pacing and ICDs) on top of optimal pharmacological therapy has been markedly expanded during the last year with new trials clarifying the possibilities with these products.

Conclusion

Treatment of CHF has advanced further with more options providing additional life-saving therapies beyond and above ACE-inhibitors and beta-blockers.

Gina Dellios | alfa
Further information:
http://www.escardio.org/vpo/ESC_congress_information/ConferenceReleases/

More articles from Health and Medicine:

nachricht Purdue cancer identity technology makes it easier to find a tumor's 'address'
16.11.2018 | Purdue University

nachricht Microgel powder fights infection and helps wounds heal
14.11.2018 | Michigan Technological University

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: UNH scientists help provide first-ever views of elusive energy explosion

Researchers at the University of New Hampshire have captured a difficult-to-view singular event involving "magnetic reconnection"--the process by which sparse particles and energy around Earth collide producing a quick but mighty explosion--in the Earth's magnetotail, the magnetic environment that trails behind the planet.

Magnetic reconnection has remained a bit of a mystery to scientists. They know it exists and have documented the effects that the energy explosions can...

Im Focus: A Chip with Blood Vessels

Biochips have been developed at TU Wien (Vienna), on which tissue can be produced and examined. This allows supplying the tissue with different substances in a very controlled way.

Cultivating human cells in the Petri dish is not a big challenge today. Producing artificial tissue, however, permeated by fine blood vessels, is a much more...

Im Focus: A Leap Into Quantum Technology

Faster and secure data communication: This is the goal of a new joint project involving physicists from the University of Würzburg. The German Federal Ministry of Education and Research funds the project with 14.8 million euro.

In our digital world data security and secure communication are becoming more and more important. Quantum communication is a promising approach to achieve...

Im Focus: Research icebreaker Polarstern begins the Antarctic season

What does it look like below the ice shelf of the calved massive iceberg A68?

On Saturday, 10 November 2018, the research icebreaker Polarstern will leave its homeport of Bremerhaven, bound for Cape Town, South Africa.

Im Focus: Penn engineers develop ultrathin, ultralight 'nanocardboard'

When choosing materials to make something, trade-offs need to be made between a host of properties, such as thickness, stiffness and weight. Depending on the application in question, finding just the right balance is the difference between success and failure

Now, a team of Penn Engineers has demonstrated a new material they call "nanocardboard," an ultrathin equivalent of corrugated paper cardboard. A square...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

“3rd Conference on Laser Polishing – LaP 2018” Attracts International Experts and Users

09.11.2018 | Event News

On the brain’s ability to find the right direction

06.11.2018 | Event News

European Space Talks: Weltraumschrott – eine Gefahr für die Gesellschaft?

23.10.2018 | Event News

 
Latest News

Purdue cancer identity technology makes it easier to find a tumor's 'address'

16.11.2018 | Health and Medicine

Good preparation is half the digestion

16.11.2018 | Life Sciences

Microscope measures muscle weakness

16.11.2018 | Life Sciences

VideoLinks
Science & Research
Overview of more VideoLinks >>>